Clark Estates Inc. NY Acquires New Position in Avanos Medical, Inc. (NYSE:AVNS)

Clark Estates Inc. NY bought a new position in shares of Avanos Medical, Inc. (NYSE:AVNS) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 493,880 shares of the company’s stock, valued at approximately $7,077,000. Avanos Medical accounts for about 1.5% of Clark Estates Inc. NY’s investment portfolio, making the stock its 14th largest holding. Clark Estates Inc. NY owned approximately 1.07% of Avanos Medical at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of AVNS. T. Rowe Price Investment Management Inc. grew its holdings in shares of Avanos Medical by 27.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company’s stock worth $47,941,000 after purchasing an additional 644,267 shares during the period. Pacer Advisors Inc. acquired a new position in Avanos Medical in the first quarter valued at about $6,056,000. Brown Advisory Inc. lifted its position in Avanos Medical by 12.0% in the fourth quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company’s stock valued at $30,329,000 after buying an additional 204,218 shares during the last quarter. Diamond Hill Capital Management Inc. purchased a new position in Avanos Medical during the first quarter worth about $2,800,000. Finally, D. E. Shaw & Co. Inc. increased its position in shares of Avanos Medical by 43.1% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company’s stock valued at $7,874,000 after acquiring an additional 148,902 shares during the last quarter. 95.17% of the stock is owned by hedge funds and other institutional investors.

Avanos Medical Price Performance

Avanos Medical stock opened at $11.81 on Wednesday. The company’s 50 day simple moving average is $12.18 and its 200-day simple moving average is $13.68. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.56 and a current ratio of 2.57. Avanos Medical, Inc. has a 1 year low of $11.21 and a 1 year high of $25.36. The company has a market capitalization of $546.09 million, a price-to-earnings ratio of -1.41 and a beta of 1.12.

Avanos Medical (NYSE:AVNS) last released its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.07. The company had revenue of $167.50 million during the quarter, compared to the consensus estimate of $161.75 million. Avanos Medical had a positive return on equity of 6.26% and a negative net margin of 55.80%. Avanos Medical’s revenue was up .8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.22 EPS. As a group, equities research analysts expect that Avanos Medical, Inc. will post 1.32 earnings per share for the current year.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.